Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Neurobiomod
- Development stage
- Unknown
- Lead developer
- Neurentis
- Administration
- Oral
01
Overview
NRNT-012201 (Neurobiomod) is a proprietary natural formulation developed by Neurentis for the management of mild depression and anxiety. The product is composed of naturally derived compounds and essential nutrients designed to support neurological health and mood stability. Unlike traditional pharmaceutical antidepressants, Neurobiomod is positioned as a nutraceutical or natural health product. According to sponsor information, the asset is currently at a commercial or revenue-generating stage rather than undergoing formal clinical trial phases, serving as a non-synthetic alternative for individuals experiencing mild psychological distress.
- Brand names
- Neurobiomod
- Other names
- NRNT-012201NRNT012201NRNT 012201
Beyond the preview
Go deeper on Neurobiomod.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neurobiomod.